User profiles for Lilian Golzarri-Arroyo

Lilian Golzarri-Arroyo

Indiana University
Verified email at indiana.edu
Cited by 566

[HTML][HTML] Ambiguity in statistical analysis methods and nonconformity with prespecified commitment to data sharing in a cluster randomized controlled trial

Y Jamshidi-Naeini, L Golzarri-Arroyo…�- Journal of Medical�…, 2024 - mhealth.jmir.org
Journal of Medical Internet Research - Ambiguity in Statistical Analysis Methods and
Nonconformity With Prespecified Commitment to Data Sharing in a Cluster Randomized Controlled …

Continuous Quality Improvement in the Substance Abuse and Mental Health Services Administration's Technology Transfer Center Network: A Process Evaluation

…, G Castillo, L Golzarri-Arroyo�- Evaluation & the�…, 2024 - journals.sagepub.com
In healthcare and related fields, there is often a gap between research and practice. Scholars
have developed frameworks to support dissemination and implementation of best practices…

[HTML][HTML] Organizational network analysis of SAMHSA's technology transfer center (TTC) network

…, K Reho, J Roberts, SKR Heil, L Golzarri-Arroyo…�- The Journal of�…, 2024 - Springer
Technology transfer centers (TTCs) facilitate the movement of evidence-based practices in
behavioral healthcare from theory to practice. One of the largest such networks is the …

[HTML][HTML] Assessing the acceptability and feasibility of remote spirometric monitoring for rural patients with interstitial lung disease: a multimethod approach

…, S Schacht, R Borton, J Vincent, L Golzarri-Arroyo…�- Respiratory�…, 2024 - Springer
Introduction Interstitial lung disease encompasses a group of rare lung conditions causing
inflammation and scarring of lung tissue. The typical method of monitoring disease activity is …

[HTML][HTML] The Feasibility of Using the National PulsePoint Cardiopulmonary Resuscitation Responder Network to Facilitate Overdose Education and Naloxone�…

…, DC Seo, M Parker, L Golzarri-Arroyo…�- JMIR Research�…, 2024 - researchprotocols.org
Background The use of naloxone, an opioid antagonist, is a critical component of the US
response to fatal opioid-involved overdoses. The importance and utility of naloxone in …

[HTML][HTML] Efficacy of supplemental oxygen in reducing the need for laser or intravitreal bevacizumab in preterm infants with stage 2 retinopathy of prematurity

…, K Hartigan, S Vegunta, C Boente, L Golzarri-Arroyo…�- BMC�…, 2024 - Springer
Background Retinopathy of prematurity (ROP) is a disease that affects preterm infants born
younger than 30 weeks of gestation. The pathophysiology of ROP involves an initial vaso-…

Design and conduct of a randomized controlled feeding trial in a residential setting with mitigation for COVID-19

…, CY Chiu, SL Dickinson, L Golzarri-Arroyo…�- Contemporary Clinical�…, 2024 - Elsevier
Background Evaluating effects of different macronutrient diets in randomized trials requires
well defined infrastructure and rigorous methods to ensure intervention fidelity and adherence…

[HTML][HTML] Promoting Trustworthiness of Science: Reproducing and Verifying Agarwal et al.'s (2022) Findings Through Collaborative Endeavors

…, NE Velasquez, L Golzarri-Arroyo…�- Journal of Alzheimer's�…, 2024 - ncbi.nlm.nih.gov
Ensuring the integrity and trustworthiness of science relies on reproducibility, a cornerstone
of the scientific process. The availability of raw data in a FAIR manner (Findable, Accessible, …

Correlates of Physical Activity, Sedentary Time, and Cardiovascular Disease Risk in Autistic Adults Without Intellectual Disabilities

…, P Shih, S Dickinson, L Golzarri Arroyo…�- Sedentary Time, and�… - papers.ssrn.com
Background: Emerging evidence indicates that autistic adults without intellectual disabilities
(ID) are at elevated risk of developing cardiovascular disease (CVD). Aims: This cross-…

Comparing reactivation and retreatment for three doses of bevacizumab in type 1 retinopathy of prematurity

J Chopra, KM Haider, CS Boente�- Journal of American Association for�…, 2024 - Elsevier
Purpose To determine timing and rates of reactivation and retreatment of type 1 retinopathy
of prematurity (ROP) after treatment with either 0.125 mg, 0.250 mg, or 0.500 mg of …